Free Newsletter
Register for our Free Newsletters
Advanced Composites
Amorphous Metal Structures
Analysis and Simulation
Asbestos and Substitutes
Associations, Research Organisations and Universities
Automation Equipment
Building Materials
Bulk Handling and Storage
CFCs and Substitutes
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

New surgical sealant technology from BTG

BTG : 15 October, 2006  (New Product)
BTG, the global technology commercialisation company, announced today it will commercialise the rights to a new surgical sealant technology, which could replace traditional suturing in surgery, as well as provide advantages over biochemical sealants currently in use.
Originally designed for ophthalmic surgery, but also applicable in general surgery, the technology has many advantages over existing suturing techniques including:

Easy to handle. The viscosity and material characteristics of the sealant allow greater flexibility of use during surgery.

Rapid tissue sealing time. This sealant has greater cohesive properties than fibrin adhesives, allowing a faster completion of the procedure and reduced healing time for incisions.

Good tolerance ensures minimal risk of patient rejection. This sealant has a lesser exothermic reaction than current cyanoacrylic adhesives and will not cause tissue ulceration. It releases in a timely fashion and does not hinder the natural healing process.

Natural body elimination. As the incision heals, the sealant is reabsorbed into the body and eliminated naturally. Fibrin adhesives are absorbed in vivo but in contrast are prone to viral contamination.

Transparency, which is ideal for ophthalmic surgery.
The technology consists of two products with complementary applications to suit the unique demands of different surgical procedures.

ADAL 1, an adhesive which provides strong adhesion and quick polymerisation. This product is ideal for procedures where speed is of the essence such as cardiovascular surgery. Recruitment for a clinical trial is underway using ADAL 1 in joining and sealing the eye muscle to the sclera following ophthalmic surgery.
ADAL 2, a sealant which offers slower polymerisation, high flexibility and prolonged manipulation time. This sealant is suited to situations where slow, delicate work is necessary. The product is very close to market with a clinical trial nearing completion in Spain.

Dr Geoffrey Porges, BTGs Executive Vice President and Director, Health, Medical & BioTechnologies, said: 'There is an increasing need for novel biomedical adhesives. The benefits of these technologies offer manufacturers the opportunity to establish unique positions and products in this emerging market.'

The market potential for this product is extensive, as the total worldwide wound closures market is valued at approximately $1.7 billion. The US adhesive tissue sealant market is projected to grow to around $400 million in 2003. The total absorbable tissue sealant market (2000) forecast for Europe is $70 million(1).

This technology has been developed at the Universidad de Alicante in Spain.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo